EGRX Eagle Pharmaceuticals, Inc.

74.12
+0.85  (1.15%)
Previous Close 73.27
Open 73.30
Price To book 10.72
Market Cap 1.14B
Shares 15,435,000
Volume 158,773
Short Ratio 7.53
Av. Daily Volume 325,574

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA submission announced January 3, 2017.
Ready-to-dilute (RTD) Pemetrexed Injection
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
Rolling NDA filing initiated November 11, 2016. Announced completion January 23, 2017. Priority review requested.
Ryanodex
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24 2015
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review
Ryanodex
Malignant hyperthermia - cancer

Latest News

  1. 9:35 am Eagle Pharma announces that 4 additional patents have been issued related to Bendeka by the USPTO
  2. Eagle Pharmaceuticals Announces New Patents Issued for Bendeka
  3. Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2016 Financial Results on March 1, 2017
  4. Eagle Pharmaceuticals to Present at 2017 RBC Capital Markets Global Healthcare Conference
  5. EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits
  6. EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina
  7. Falling Earnings Estimates Signal Weakness Ahead for Eagle Pharmaceuticals (EGRX)
  8. Eagle Pharmaceuticals Wraps Up Ryanodex NDA Submission
  9. Eagle Pharmaceuticals Completes NDA Submission for Ryanodex for Exertional Heat Stroke to FDA
  10. New Strong Sell Stocks for January 16th
  11. EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  12. EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  13. Eagle Pharmaceuticals, Inc. – Value Analysis (NASDAQ:EGRX) : January 10, 2017
  14. Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : January 9, 2017
  15. Eagle Pharma downgraded by Mizuho
  16. EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  17. Eagle Pharmaceuticals to Present at J.P. Morgan 35th Annual Healthcare Conference
  18. Eagle Pharmaceuticals’ Pemetrexed NDA Submitted for Review
  19. Eagle Pharmaceuticals’ Pemetrexed NDA Submitted for Review
  20. Myriad Genetics' Unit Releases Favorable Data on Vectra DA